Biogen
Biogen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of neurological disease research since its founding in 1978. With a strong presence in North America, Europe, and Asia, Biogen focuses on developing innovative therapies for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. Renowned for its pioneering work in monoclonal antibodies, Biogen's core products include the multiple sclerosis treatments Tecfidera and Ocrevus, which are distinguished by their efficacy and safety profiles. The company has achieved significant milestones, including the first FDA approval of a treatment for spinal muscular atrophy in 2016. As a key player in the biotechnology industry, Biogen continues to push the boundaries of science, solidifying its market position through a commitment to research and development, and a robust pipeline of potential therapies.
DitchCarbon Score
How does Biogen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biogen's score of 65 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Biogen's reported carbon emissions
In 2023, Biogen reported total greenhouse gas emissions of approximately 361,715,000 kg CO2e, with Scope 1 emissions at about 57,611,000 kg CO2e and Scope 2 emissions at approximately 373,000 kg CO2e. The company’s Scope 3 emissions were significant, totalling around 304,105,000 kg CO2e, highlighting the importance of addressing emissions across its entire value chain. Biogen has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2045. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 55% by 2032, using 2019 as the baseline year. Furthermore, Biogen plans to achieve a 100% reduction in these emissions by 2040. In addition, it aims to reduce Scope 3 emissions by 90% by 2045. To support these goals, Biogen is committed to ensuring that 80% of its suppliers, based on spend for purchased goods and services and capital goods, will have science-based targets by 2025. This comprehensive approach underscores Biogen's dedication to sustainability and its proactive stance in combating climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 60,179,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 187,000 | 000,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 262,358,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biogen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
